UY27107A1 - Método para identificar ligandos de receptores de progesterona específicos para isoformas y ligandos de receptores de progesterona selectivos para tejidos. - Google Patents

Método para identificar ligandos de receptores de progesterona específicos para isoformas y ligandos de receptores de progesterona selectivos para tejidos.

Info

Publication number
UY27107A1
UY27107A1 UY27107A UY27107A UY27107A1 UY 27107 A1 UY27107 A1 UY 27107A1 UY 27107 A UY27107 A UY 27107A UY 27107 A UY27107 A UY 27107A UY 27107 A1 UY27107 A1 UY 27107A1
Authority
UY
Uruguay
Prior art keywords
progesterone
legends
isoforms
selecting
receiver
Prior art date
Application number
UY27107A
Other languages
English (en)
Inventor
Ulrike Fuhrmann
Christa Hegele-Hartung
Michael Klotzbuecher
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY27107A1 publication Critical patent/UY27107A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Método para identificar ligandos específicos para isoformas del receptor de progesterona. Un primer método para identificar ligandos de receptores de progesterona selectivos para tejidos. Métodos que comprenden seleccionar ligandos selectivos para tejidos. Métodos que comprenden seleccionar ligandos selectivos para la isoforma del receptor de progesterona A o la isoforma del receptor de progesterona B. Un segundo método que comprende pruebas in vivo en tejidos blanco. La presente invención también se relaciona con un ligando específico para isoformas del receptor de progesterona y/o selectivo para tejidos identificado mediante los métodos de acuerdo con la presente invención, y se relaciona además con las células, un equipo de ensayo respectivo y usos médicos.
UY27107A 2000-12-28 2001-12-28 Método para identificar ligandos de receptores de progesterona específicos para isoformas y ligandos de receptores de progesterona selectivos para tejidos. UY27107A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25831200P 2000-12-28 2000-12-28
US30587501P 2001-07-18 2001-07-18

Publications (1)

Publication Number Publication Date
UY27107A1 true UY27107A1 (es) 2002-03-22

Family

ID=26946565

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27107A UY27107A1 (es) 2000-12-28 2001-12-28 Método para identificar ligandos de receptores de progesterona específicos para isoformas y ligandos de receptores de progesterona selectivos para tejidos.

Country Status (8)

Country Link
EP (1) EP1373888A2 (es)
JP (1) JP2004516841A (es)
AR (1) AR032050A1 (es)
AU (1) AU2002219218A1 (es)
NO (1) NO20032969L (es)
PE (1) PE20020784A1 (es)
UY (1) UY27107A1 (es)
WO (1) WO2002054064A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113801889A (zh) * 2021-09-18 2021-12-17 中国农业科学院农业质量标准与检测技术研究所 细胞筛选模型及其构建方法和应用、酵母菌及其制备方法和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003209720A1 (en) * 2002-03-11 2003-09-22 Schering Ag 5-{2-hydroxy-3-'1-(3-trifluoromethylphenyl)-cyclopropyl!-propionylamino}-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy
DE102007049630A1 (de) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007023614A1 (de) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2070909A1 (de) 2007-12-15 2009-06-17 Bayer Schering Pharma AG Nichtsteroidale Progesteronrezeptor-Modulatoren

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
DE4235220A1 (de) * 1992-10-13 1994-06-16 Schering Ag Gestagen wirksame 19,11ß-überbrückte 4-Estrene
DE4337416A1 (de) * 1993-10-27 1995-05-04 Schering Ag 10,11beta-C¶2¶-überbrückte Steroide
US5506102A (en) * 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
DE4413185A1 (de) * 1994-04-12 1995-10-19 Schering Ag 11beta,19-überbrückte 13alpha-Alkylsteroide
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113801889A (zh) * 2021-09-18 2021-12-17 中国农业科学院农业质量标准与检测技术研究所 细胞筛选模型及其构建方法和应用、酵母菌及其制备方法和应用

Also Published As

Publication number Publication date
WO2002054064A3 (en) 2003-10-16
JP2004516841A (ja) 2004-06-10
WO2002054064A2 (en) 2002-07-11
NO20032969D0 (no) 2003-06-27
PE20020784A1 (es) 2002-10-03
AR032050A1 (es) 2003-10-22
EP1373888A2 (en) 2004-01-02
AU2002219218A1 (en) 2002-07-16
NO20032969L (no) 2003-08-28

Similar Documents

Publication Publication Date Title
TW200600778A (en) An analyte measuring system which prevents the reuse of a test strip
ATE529748T1 (de) Kombinationstest für alkohol und drogen
ES2116578T3 (es) Procedimiento y dispositivo para evaluar la aptitud de biopolimeros.
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
SE9302183D0 (sv) Apparatus and method for in vivo monitoring of physiological pressures
UY27107A1 (es) Método para identificar ligandos de receptores de progesterona específicos para isoformas y ligandos de receptores de progesterona selectivos para tejidos.
TW366279B (en) Method for assessing disposable absorbent articles with improved skin dryness performance and with improved skin aeration
ATE350662T1 (de) Markerproteine für prostatakrebs
AR013048A1 (es) Composicion para el tenido de fibras queratinicas con un colorante directo cationico y un polimero espesante, procedimiento de tenido y dispositivo de tenido
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
AR048135A1 (es) Uso de gen de amiloide a serico en el diagnostico y tratamiento del glaucoma y en la identificacion de agentes anti-glaucoma.
ATE375517T1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
YU90301A (sh) Konjugati i postupci za njihovu proizvodnju i njihova upotreba za transport molekula kroz biološke membrane
ES2156105T3 (es) Derivados de amino-fenoles sustituidos en n y o, productos intermedios para su preparacion, su utilizacion como substratos para hidrolasas, un correspondiente procedimiento de determinacion y un agente de diagnostico apropiado para ello.
ATE259379T1 (de) Fluoresceinisothiocyanat-(fitc)-sinistrin, seine herstellung und verwendung
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
ES2167625T3 (es) Telas no tejidas de grafito como capas funcionales en estuches para pruebas diagnosticas.
DE3784468D1 (de) Testbares mehrmodus-zaehlernetz und methode zur durchfuehrung des tests.
Mennemeier et al. Crossover by line length and spatial location
ES2196037T3 (es) Calibrador para uso en un metodo de ensayo para detectar un factor v de coagulacion defectuoso.
EG24879A (en) Test element and method for testing blood
GB9827533D0 (en) Method and apparatus for functional test of communication port
ES2109109T3 (es) Procedimiento de ensayo de materias activas en cabellos depilados.
AR080471A1 (es) Participacion de la via de androgenos/receptores de androgenos en la enfermedad de fabry
TW200716978A (en) Method

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150420